Pentax Medical Sustainability Profile
Pentax Medical, a division of Hoya Corporation, is a leading provider of innovative medical imaging solutions, headquartered in Japan. Established in 1919, the company has a rich history of advancements in endoscopy and minimally invasive surgical technologies, serving healthcare professionals across the globe, particularly in Europe, Asia, and North America. Specialising in endoscopic equipment, Pentax Medical offers a range of products, including high-definition endoscopes and imaging systems that enhance diagnostic accuracy and patient outcomes. Their commitment to quality and innovation has positioned them as a trusted partner in the medical community, with notable achievements in developing user-friendly devices that prioritise patient safety and comfort. With a strong market presence, Pentax Medical continues to lead the way in transforming healthcare through cutting-edge technology.
DitchCarbon Score
How does Pentax Medical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pentax Medical's score of 28 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pentax Medical's reported carbon emissions
In 2025, Pentax Medical reported total carbon emissions of approximately 788,000 kg CO2e, a decrease from about 866,000 kg CO2e in 2023. The emissions breakdown for 2025 includes 52,000 kg CO2e from Scope 1, 29,000 kg CO2e from Scope 2, and a significant 707,000 kg CO2e from Scope 3 emissions. This trend indicates a commitment to reducing overall emissions, particularly in Scope 3, which often represents the largest share of a company's carbon footprint. In 2022, the company recorded total emissions of about 886,000 kg CO2e globally, with similar Scope 1 and Scope 2 figures of 52,000 kg CO2e and 29,000 kg CO2e, respectively. However, Scope 3 emissions were notably higher at approximately 804,000 kg CO2e. Despite these figures, Pentax Medical has not publicly disclosed specific reduction targets or initiatives, nor does it appear to have set Science-Based Targets (SBTi) or other formal climate pledges. The emissions data is cascaded from its parent company, HOYA Corporation, indicating a corporate commitment to sustainability at multiple levels. Overall, while Pentax Medical has shown a reduction in emissions from 2023 to 2025, the absence of defined reduction targets suggests an area for potential improvement in their climate strategy.
How Carbon Intensive is Pentax Medical's Industry?
How Carbon Intensive is Pentax Medical's Location?
Pentax Medical's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pentax Medical has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
